Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments

Executive Summary

CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.

Advertisement

Related Content

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies
It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug
Bluebird Lays Some New Eggs, But They'll Take Time To Hatch
Bluebird Bio's Zynteglo Flies Through Its CHMP Review
Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock
J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA's Gottlieb

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel